Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Tax Provisions (2020 - 2025)

Ironwood Pharmaceuticals' Tax Provisions history spans 7 years, with the latest figure at $27.9 million for Q3 2025.

  • For Q3 2025, Tax Provisions rose 104.25% year-over-year to $27.9 million; the TTM value through Sep 2025 reached $77.6 million, up 3.99%, while the annual FY2025 figure was $46.0 million, 28.47% down from the prior year.
  • Tax Provisions for Q3 2025 was $27.9 million at Ironwood Pharmaceuticals, up from $14.2 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $32.1 million in Q4 2023 and bottomed at -$336.9 million in Q2 2021.
  • The 5-year median for Tax Provisions is $15.5 million (2022), against an average of -$7.0 million.
  • The largest YoY upside for Tax Provisions was 3997.22% in 2022 against a maximum downside of 969.91% in 2022.
  • A 5-year view of Tax Provisions shows it stood at $4.9 million in 2021, then crashed by 969.91% to -$42.4 million in 2022, then surged by 175.72% to $32.1 million in 2023, then tumbled by 32.26% to $21.7 million in 2024, then rose by 28.52% to $27.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Tax Provisions are $27.9 million (Q3 2025), $14.2 million (Q2 2025), and $21.7 million (Q4 2024).